ISRCTN ISRCTN48262326
DOI https://doi.org/10.1186/ISRCTN48262326
Integrated Research Application System (IRAS) 1013562
Sponsor Sanofi (France)
Funder Sanofi France
Submission date
03/07/2026
Registration date
03/07/2026
Last edited
03/07/2026
Recruitment status
No longer recruiting
Overall study status
Deferred
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Contact information

Dr Benjamin Monaghan
Public, Scientific, Principal investigator

Fortrea Clinical Research Unit (Drapers Yard)
Drapers Yard, Marshall St, Holbeck
Leeds
LS11 9EH
United Kingdom

Phone +44 (0) 113 301 3512
Email benjamin.monaghan@fortrea.com

Study information

Primary study designInterventional
AllocationRandomized controlled trial
MaskingOpen (masking not used)
ControlUncontrolled
AssignmentCrossover
PurposePharmacokinetic
Scientific titleDeferred registration: Fortrea code 780279 [Full scientific title to be added on or before the deferral expiry date]
Study objectives The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
Ethics approval(s)

Approved 17/04/2026, London - Riverside REC (2nd Floor, 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; no telephone number provided; riverside.rec@hra.nhs.uk), ref: 26/LO/0071

Health condition(s) or problem(s) studiedThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
InterventionThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
Intervention typeDrug
PhasePhase I
Drug / device / biological / vaccine name(s)The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
Primary outcome measure(s)
  1. The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. [Outcome] measured using [measure] at [timepoint]
Key secondary outcome measure(s)
Completion date07/10/2026

Eligibility

Participant type(s)
Age groupMixed
Lower age limit0 Years
Upper age limit1 Year
SexAll
Target sample size at registration16
Key inclusion criteriaThe Health Research Authority has approved a deferral. Full details will be added to the trial record (including age limits) on or before the deferral expiry date
Key exclusion criteriaThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
Date of first enrolment28/08/2026
Date of final enrolment28/08/2026

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Fortrea Clinical Research Unit (Drapers Yard)
Drapers Yard, Marshall St, Holbeck
Leeds
LS11 9EH
England

Results and Publications

Individual participant data (IPD) Intention to shareNo

Editorial Notes

03/07/2026: Trial's existence confirmed by London - Riverside REC.